Why Is REVOLUTION MEDICINES (RVMD) Stock Moving Today?
By the Top Tier Newswire AI Desk · August 26, 2026 at 3:07 PM ET · reviewed against 14 wire stories
REVOLUTION MEDICINES (RVMD) is drawing unusual attention today. Our newswire has captured 14 stories on RVMD across 11 sources in the last 36 hours, with AI sentiment reading bullish (avg 71/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why RVMD stock is moving today
Shares of Revolution Medicines (RVMD) are moving after the company received U.S. Food and Drug Administration approval for RASONQUE (daraxonrasib), the first broad RAS-targeted medicine for metastatic pancreatic cancer. The approval, announced on August 26, 2026, has triggered market activity as the drug is now available by prescription with patient support. The stock opened lower but has since recovered some ground, with a session high of $218.30 and a last price of $209.93.
What Happened
The FDA approval of RASONQUE marks a significant milestone for Revolution Medicines, which has been developing the drug as a targeted therapy for advanced pancreatic cancer. The therapy demonstrated a median overall survival of 13.2 months in clinical trials compared to 6.7 months with chemotherapy. Revolution Medicines has priced Rasonque at $39,800 for a 30-day supply. The company filed an 8-K on August 26 disclosing the approval. The approval has been highlighted by several financial and industry outlets as a potential catalyst for the stock.
What The Data Shows
Intraday trading has shown a volatile session, with the stock opening at $209.32, a 1.0% gap down from the prior close. The stock reached a high of $218.30 at 1:45 PM ET but fell to a low of $198.91 at 10:45 AM ET. Trading volume has been 2.0 million shares, which is 0.7 times the 3-month average. The stock has printed both a 52-week high and a 52-week low on the same day. Over the last 30 days, sentiment has improved from an average of 66 to 70 out of 100. In the last 90 days, insider transactions have totaled 12 sells worth $54.9 million, with no insider buys.
What To Watch
Revolution Medicines has no scheduled earnings date in the near term. Investors may want to monitor the breadth of analyst coverage and any further developments in the company’s pipeline or market access for RASONQUE.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
RVMD · Aug 26 session (5-min) · +2.74% vs prior close · updated 8:52 PM ETAI sentiment, last 36h · averaged over 14 stories · 71/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
17d agoTipRanksBULLISH 85Product/PR
Revolution Medicines Wins FDA Approval for RASONQUE Therapy
The latest update is out from Revolution Medicines ( ($RVMD) ). On August 26, 2026, Revolution Medicines received U.S. Food and Drug Administration approval for RAS...
17d agoThe FlyBULLISH 59Product/PR
Revolution Medicines prices Rasonque at $39,800 for 30-day supply
Revolution Medicines announces FDA approval of Rasonque in adults
17d agoStockTitanBULLISH 82Product/PR
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
In the trial, median overall survival was 13.2 months versus 6.7 with chemotherapy; the 300 mg pill is now available by prescription with patient support.
17d agoTipRanksBULLISH 73Product/PR
Revolution Medicines Stock (RVMD) Boosted By FDA Pancreatic Cancer Approval
Shares in oncology drugs group Revolution Medicines ($RVMD) were higher today after the U.S. Food and Drug Administration approved its treatment for advanced pancre...
17d agoCNBCBULLISH 73Product/PR
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
17d agoBarron'sBULLISH 78Product/PR
Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →